Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;197(7):657-660.
doi: 10.1007/s00066-021-01788-z. Epub 2021 Jun 10.

[Lorlatinib: a promising drug in the future treatment of advanced ALK-positive non-small-cell lung cancer]

[Article in German]
Johanna Richter  1 , Jürgen Dunst  2
Affiliations
Comment

[Lorlatinib: a promising drug in the future treatment of advanced ALK-positive non-small-cell lung cancer]

[Article in German]
Johanna Richter et al. Strahlenther Onkol. 2021 Jul.
No abstract available

PubMed Disclaimer

Comment on

  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
    Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.

References

    1. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther. 2007;6(12):3314–3322. doi: 10.1158/1535-7163.MCT-07-0365. - DOI - PubMed
    1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. doi: 10.1038/nature05945. - DOI - PubMed
    1. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18(5):1472–1482. doi: 10.1158/1078-0432.CCR-11-2906. - DOI - PMC - PubMed
    1. Bauer TM, Shaw AT, Johnson ML, Navarro A, Gainor JF, Thurm H, et al. Brain penetration of Lorlatinib: cumulative Incidences of CNS and non-CNS progression with Lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer. Target Oncol. 2020;15(1):55–65. doi: 10.1007/s11523-020-00702-4. - DOI - PMC - PubMed
    1. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–838. doi: 10.1056/NEJMoa1704795. - DOI - PubMed